Teva will market the company’s inhalers exclusively in Israel, after signing a marketing and distribution agreement with Syqe® in 2016.
Bedrocan highlights SyqeAir’s TGA Approval in Australia
An article by Bedrocan about Syqe® receiving the Therapeutic Goods Administration (TGA) approval for the SyqeAir inhaler in Australia. This significant regulatory milestone is a step forward in the global expansion of our treatment.